Why It Matters
The Senate Health, Education, Labor, and Pensions Committee will hold a legislative hearing on July 22 to review a slate of healthcare bills that target longstanding policy bottlenecks, including insulin affordability, nursing workforce shortages, and epilepsy research coordination.
The hearing reflects congressional interest in addressing persistent healthcare gaps, though the bills face mixed industry engagement. Only the workforce expansion measure has attracted substantial lobbying attention, suggesting a disconnect between legislator priorities and stakeholder mobilization on insulin pricing and privacy protections.
The Bills Under Review
The INSULIN Act of 2026 would cap out-of-pocket insulin costs at $35 for a 30-day supply for insured patients beginning Jan. 1, 2027, before lowering the cap to 25% of the negotiated price in 2028. The bill also would eliminate deductibles for selected insulin products, prohibit certain regulatory petitions that delay generic and biosimilar competition, establish a $100 million pilot program for uninsured patients in 10 states, and require pharmacy benefit managers and insurers to pass through 100% of insulin-related rebates to health plans.
The nursing workforce reauthorization bill would extend federal funding for health workforce development programs through 2030 and increase funding for child and adolescent mental health workforce programs from $28.5 million to $42.7 million annually. The legislation also would expand pediatric workforce development, broaden eligibility requirements and modify grant renewal timelines for Area Health Education Centers.
Other measures on the agenda include a health information privacy reform bill, an epilepsy research coordination act, a biosimilar regulatory streamlining bill, and a pharmacy compounding oversight measure.
Lobbying Activity and Industry Response
The nursing workforce bill has attracted lobbying activity from Rubin Health Policy Consulting LLC and the Association of American Medical Colleges. However, the insulin pricing legislation has generated no recorded lobbying activity, a striking absence given the pharmaceutical industry's typical opposition to price control measures.
Hearing Details
Sen. Bill Cassidy (R-LA) chairs the committee, and Sen. Bernie Sanders (I-VT) serves as ranking member.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article